Studies show that mutations in the PI3K/AKT/mTOR pathway are present in even over 70% of breast cancer cases, which is why drugs targeting its elements are widely used, especially in combined treatment in patients with resistance to hormonal therapy, achieving better effects than drugs from these groups used separately [12]. Here, MTOR is linked to breast carcinoma.